Drug Combination Details
| General Information of the Combination (ID: C22793) | |||||
|---|---|---|---|---|---|
| Name | Paclitaxel NP Info | + | PNC-27 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | MDM2 | Molecule Info | ||
| In-vivo Model | PNC-27 was tested in an intraperitoneal mouse model of ovarian cancer. | |||||
| Experimental
Result(s) |
PNC-27 could target cells surviving paclitaxel and improve its antitumor effect. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer. Ann Clin Lab Sci. 2017 May;47(3):271-281. | |||
